The World Health Organization has long recognized the need for a global harmonization of standards for biologics worldwide. In response, the United Kingdom's National Institute for Biological Standards and Control has developed the first international standard for infliximab.
The World Health Organization has long recognized the need for a global harmonization of standards for biologics worldwide. In response, the United Kingdom's National Institute for Biological Standards and Control (NIBSC) has developed the first international standard (IS) for infliximab, which targets tumor necrosis factor (TNF).
A recent paper describes how a candidate preparation coded 16/170 was found to be suitable as an IS for bioactivity for infliximab. The hope is that future continued studies such as these, examining standardization, will help promote biosimilar development, leading to lower drug costs worldwide, the authors said.
The issue has arisen because postapproval manufacturing changes in highly regulated markets can potentially result in changes in the product over time. Reference infliximab, for example, has gone through approximately 50 such changes since approval. As multiple biosimilars of a given reference product enter the marketplace, these individual products will all undergo their own changes, and could experience drift from the originator product.
Every product’s manufacturer has its own reference standards (a term not to be confused with reference product) against which it measures a product’s consistency over time. As such, there is an increasing need for harmonization of these in-house standards with a public standard that can serve as a benchmark for the reference product and all biosimilars.
The infliximab IS from NIBSC is intended to support in vitro bioassay calibration and validation by defining international units (IU) of bioactivity. The authors noted that the proposed units are not intended to revise product labelling or dosing requirements, since these decisions are made by regulators.
In this study, each ampule was assigned values of 500 IU of TNF neutralizing activity and 500 IU of binding activity. Two preparations of infliximab were formulated and lyophilized at NIBSC. The study involved using in vitro cell-based bioassays (TNF neutralization, antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity) and binding assays.
For TNF neutralization, between 74% and 83% of the assays performed were valid depending on the standard and the assay readout type. The assays proved to be very robust, even in the absence of a common standard. No one particular assay method was more variable; in addition, all reported potencies were similar.
The most variable assays in this study were the binding assays. Although this might be due to the smaller number of assays performed compared to the TNF neutralization assays, there could be several other contributing factors. Unlike TNF neutralization, the methods used were diverse and included ELISA, FRET and SPR platforms.
Overall, when infliximab products were assayed relative to in-house standards, there was significant variation in the relative potency estimates reported. However, the introduction of a common bioassay reference standard reduced inter-laboratory variability.
As more infliximab products come to market, they will all adopt their own lifecycle. It is important to ensure that the quality of products are aligned after different authorizations. Of note, this was the first international collaborative study, consisting of 26 participants in 15 countries.
Reference
Metcalfe C, Dougall T, Bird C, et al. The first World Health Organization international standard for infliximab products: A step towards maintaining harmonized biological activity. [published online November 5, 2018]. mAbs. doi:10.1080/19420862.2018.1532766.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.